PI
NKTR icon

Putnam Investments’s Nektar Therapeutics NKTR Stock Holding History

Putnam Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,440
Closed -$7.63M – 825
2021
Q1 		$7.63M Buy
+25,440
New +$7.92M 0.01% 425
2018
Q4 		– Sell
-363
Closed -$332K – 1040
2018
Q3 		$332K Sell
363
-463
-56% -$395K ﹤0.01% 979
2018
Q2 		$605K Sell
826
-2,915
-78% -$3.36M ﹤0.01% 917
2018
Q1 		$5.96M Sell
3,741
-1,943
-34% -$2.5M 0.01% 484
2017
Q4 		$5.09M Buy
5,684
+1,165
+26% +$689K 0.01% 514
2017
Q3 		$1.63M Buy
+4,519
New +$1.41M ﹤0.01% 823
2015
Q2 		– Sell
-8,752
Closed -$1.45M – 1530
2015
Q1 		$1.45M Sell
8,752
-342
-4% -$70.3K ﹤0.01% 1133
2014
Q4 		$2.11M Sell
9,094
-49
-0.5% -$10.5K ﹤0.01% 1011
2014
Q3 		$1.66M Buy
9,143
+153
+2% +$29.3K ﹤0.01% 1073
2014
Q2 		$1.73M Buy
8,990
+12
+0.1% +$2.12K ﹤0.01% 1064
2014
Q1 		$1.63M Buy
+8,978
New +$1.78M ﹤0.01% 1092

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Putnam Investments's NKTR Position: Q2 2021 in Review

Putnam Investments sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 25,440 shares — an estimated $7.63M sold.

Putnam Investments first reported a position in NKTR in Q1 2014 and held it in 11 quarters. The position peaked at $7.63M in Q1 2021. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

  • Putnam Investments reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Putnam Investments sold 25,440 Nektar Therapeutics shares in Q2 2021, an estimated $7.63M.
  • Putnam Investments first reported a position in Nektar Therapeutics in Q1 2014 and held it in 11 quarters.
  • Putnam Investments's Nektar Therapeutics position peaked at $7.63M in Q1 2021.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on Putnam Investments's 13F filing for Q2 2021, filed 16 Aug 2021.